Mediaire's On-Premise AI Has Landed in 350 European Radiology Clinics

For a patient waiting on a diagnosis of dementia, the difference between a 20-minute manual MRI analysis and a 5-minute automated one is measured in anxiety. For the radiologist facing a growing backlog, it’s a matter of capacity. Mediaire, a Berlin-based startup founded in 2018, is betting that the path to scaling clinical AI runs not through the cloud, but through the hospital’s own server room. Its suite of on-premise, CE-marked software tools for MRI analysis is now deployed in more than 350 hospitals and clinics across Europe, a footprint that just secured a €12 million Series A to fuel global expansion [Radiology Business, Dec 2024].

A Wedge of Zero-Click Automation

Mediaire’s products,mdbrain, mdprostate, and mdknee,are certified as medical devices and designed to integrate directly into a hospital’s existing radiology information system. The core proposition is workflow efficiency: the software automatically analyzes MRI scans and generates quantitative reports, a process that typically takes 3-5 minutes for a brain scan versus 20 or more minutes done manually [mediaire.ai/mdbrain, 2026]. The company claims this can reduce reading time for dementia diagnosis cases by up to 57% [LinkedIn/Tonia Maria Michaely, 2026]. The ‘wedge’ is a promise of smooth, zero-click automation that respects the stringent data privacy regulations of European healthcare, where patient data often cannot leave the hospital firewall. This on-premise focus has allowed mediaire to build a substantial European base, with its monthly recurring revenue tripling since the first quarter of 2023 [Gateway Ventures, 2024].

The Team and the Traction

The company’s technical credibility is anchored by its founders, who bring deep domain expertise in both MRI physics and clinical radiology. CEO Dr. Andreas Lemke holds a PhD in advanced MRI acquisition techniques, while co-founder Prof. Dr. Henrik Michaely is a practicing radiologist and managing partner at a large German radiology practice [HQ Imaging/about, 2026] [LinkedIn, 2026]. This blend of technical and clinical insight is a deliberate counter to more generic AI imaging approaches. Their traction is reflected in a recent, oversubscribed €12 million funding round led by LBO France, with participation from IBB Ventures, Wille Finance, and existing investors HTGF, LIFTT, and Gateway Ventures [Radiology Business, Dec 2024]. The capital is earmarked for international growth, though the company’s public materials do not yet mention pursuing U.S. Food and Drug Administration clearance, a critical gate for the American market.

The company’s funding history shows a step-up from seed to a significant Series A, enabling its scaling ambitions.

2020 Seed | 2.43 | M USD
2024 Series A | 12.7 | M USD

The Competitive and Regulatory Landscape

Mediaire operates in a crowded field of AI radiology analytics firms, competing with players like Quibim, Icometrix, and Perspectum. Its differentiation rests on a combination of certified, organ-specific applications and its entrenched on-premise deployment model. However, this very strength introduces a key strategic question for its next phase. The architecture that eased adoption in privacy-conscious Europe may present friction in markets where cloud-based SaaS is the expected norm. Furthermore, the lack of FDA clearance limits near-term opportunity in the world’s largest healthcare market. The company’s expansion playbook will need to navigate these divergent regulatory and technical landscapes. Mediaire’s recent partnerships with sector giants like Bayer (through its Calantic platform) and imaging IT leader Sectra suggest it is building the commercial bridges needed for the next leg [TechFundingNews, Dec 2024].

The Patient at the Center of the Pixel

Ultimately, the value of any diagnostic tool is measured at the patient level. Mediaire’s mdbrain is targeted at a population facing neurodegenerative diseases like Alzheimer’s, where early and accurate diagnosis is crucial for management and care planning. The standard of care today often involves a radiologist manually segmenting and measuring brain structures from an MRI,a tedious, time-consuming process subject to inter-reader variability. By providing consistent, quantitative volumetry in minutes, tools like mdbrain aim to reduce diagnostic delay and free up specialist time for more complex cases. The next twelve months will test whether mediaire’s European clinical validation and on-premise expertise can translate into a global growth story, or if it will need to adapt its model for cloud-first markets. For now, its footprint in 350 clinics is a substantive proof point that automation, when designed for the clinician’s workflow and the patient’s privacy, can find a willing audience.

Sources

1. [Radiology Business, Dec 2024] Radiology AI firm Mediaire raises nearly $12.7M in financing | https://radiologybusiness.com/topics/artificial-intelligence/radiology-ai-firm-mediaire-raises-nearly-127m-financing
2. [TechFundingNews, Dec 2024] AI meets radiology: German startup mediaire bags €12M | https://techfundingnews.com/ai-meets-radiology-german-startup-mediaire-bags-e12m-to-transform-the-way-radiologists-work/
3. [Gateway Ventures, 2024] mediaire - Gateway Ventures | https://gateway.ventures/en/startupsnew/mediaire/
4. [mediaire.ai, 2026] mdbrain - AI-based solution for quantitative neuroimaging | https://mediaire.ai/en/mdbrain/
5. [LinkedIn/Tonia Maria Michaely, 2026] Post on reading time reduction | https://in.linkedin.com/company/mediaire
6. [HQ Imaging, 2026] About | HQ Imaging | http://hq-imaging.com/about
7. [LinkedIn, 2026] mediaire company page | https://in.linkedin.com/company/mediaire
8. [Crunchbase, Dec 2020] Seed Round - Mediaire | https://www.crunchbase.com/funding_round/mediaire-seed--c5aaab03